Retina

Advanced Retinal Therapy will be held in Vienna, Austria on 3 December 2011. At this event updates, trends and controversies in retinal tehrapy will be discussed in symposia, key-note lectures and a panel discussion session.

The National Institute for Health and Clinical Excellence (NICE) has recommended Ozurdex for the treatment of macular oedema caused by central retinal vein occlusion (CRVO).

Anticoagulation (warafin) therapy was linked to a higher risk of post vitreoretinal surgery (VRS) bleeding in comparison with antipletelet (aspirin, clopidogrel) therapy vitreoretinal.

Anti-vascular endothelial growth factor agent well-tolerated, met primary efficacy endpoint.

The answer may be found in the masking effects of catract upon pre-existing disease

OTEurope speaks with Dr Wolfgang Schalch about 'Critical parameters for lutein delivery systems' and the Actilease system.

This new technology will enable surgeons to perform treatments more accurately and comfortably in a short period of time.

Diagnostic and prognostic capabilities at the early stages of retinal diseases could be improved as a result of adaptive optics.

Dr Sunir Gard reveals some of the more common problems that can be encountered with MIVS and how to cope with them.

First in-human study of human umbilical tissue-derivedcaeels as a therapy for retinal degenerative diseases shows promise.

Dr Sebasiten Wolf describes how SD-OCT has improved the visualization of intraretinal morphologic feaures both quantatively and qualatively.

A case study involving a patient with a macular pucker with a partial posterior vitreous detachment

A novel nanosecond laser therapy has stopped the progression of age-related macular degeneration (AMD) and resulted in resolution of drusen and improved visual function in patients with early-stage high-risk AMD.

A specific diode laser is the latest technology to perform several different laser procedures in the ophthalmic practice. Its multi-use capabilities for glaucoma and retinal disease make it a strong choice for the office setting.

Combined genomic and proteomic biomarkers are seemingly the most effective method for predicting progression.

A report on the status of the 5-year-old ongoing MacTel Project, which is slowly answering questions surrounding the disease.

The efficacy and safety of two doses of a fluocinolone acetonide intravitreal insert for the treatment of DME were investigated in two sham-controlled phase III studies

Results of a recent clinical study provide promising evidence of the value of ultra-widefield fundus autofluorescence (FAF) imaging in the evaluation of age-related macular degernation (AMD)

A rare case of bilateral pigmented atrophic changes in the macular region associated with topiramate treatment for chorioathetosis in a young female is reported.

Results from preclinical testing including a formal Good Laboratory Practice toxicity study, support the safety of a gene transfer agent, AAV2-sFLT01, when administered intravitreally. A phase I safety and tolerability study of this agent is currently underway.

Study shows little difference between these forms of endotamponade in patients with PVR

New performance assessments suggest retinal prothesis augments native vision

Positive pooled results from the MIVI-TRUST phase III programme are a sign that a microplasmin one-off injection will be a real alternative to surgery

Doctors may be the first clinicians to detect the presence of a sexually transmitted disease (STD) when discovering ocular manifestations associated with STDs. However, since many of the ocular manifestations of STDs can be present with other conditions, further work is required.

Dr Michael Trese explains how a web-based disease management imaging system could enhance screening for retinopathy of prematurity through acquisition and reading of weekly digital retinal images, hospital support and more opportunities for parental involvement.

Investigational agent shown to be superior to placebo in two historic multicentre studies

Doctors place focus on delivery of care

Retinal surgeons refine technology, instrumentation to optimize safety and efficacy

VisionCare&#;s implantable telescope for end-stage AMD has finally been given FDA approval. The device, discussed in depth in Ophthalmology Times Europe July 2007, was given CE approval three years ago but has subsequently been undergoing rigorous clinical trials in the United States.

For neovascular AMD sufferers, this combination therapy may offer an alternative to continual anti-VEGF injections